News and Trends 26 Jul 2022 New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […] July 26, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jul 2022 Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […] July 26, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2022 Almirall launches new call to find innovative therapies for skin diseases A new call for new therapies to treat skin diseases has been launched by global Spanish-based biopharmaceutical company, Almirall, S.A. This is the seventh call through AlmirallShare – an open innovation platform for proposals to establish collaborations in dermatological research. The aim of this year’s edition is to find new partnership opportunities for assets in […] July 21, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Positive results for drug combination used to treat rare blood cancer Exploratory analysis of anti-cancer drug, navitoclax, combined with ruxolitinib – a medication for the treatment of intermediate or high-risk myelofibrosis (MF) – has given positive results in a study. The data, announced by US biopharma company, AbbVie, comes from cohort 3 of a phase 2 REFINE study in Janus kinase (JAK) inhibitor naïve patients with […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jul 2022 Trial for drug targeting cancerous tumors begins in China A phase 1 trial to investigate a drug for treating people with advanced malignant neoplasms has begun in China. HUTCHMED announced the trial of anti-CD47 monoclonal antibody HMPL-A83 on Friday (July 15). It is the thirteenth innovative oncology drug candidate discovered in-house by HUTCHMED and it is the company’s second large molecule drug candidate to […] July 18, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Boston startup bags $40M Series A to smash preclinical bottlenecks The U.S. company Manifold Bio has raised $40 million in a Series A round to bankroll protein barcoding technology that could speed up the preclinical development of targeted cancer drugs. Two years after bagging a $5.4 million seed investment, the Boston-based protein drug developer Manifold Bio has hit the headlines with a $40 million round […] July 14, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Telo Genomics launches clinical study of drug resistance test for multiple myeloma Canadian biotech company Telo Genomics Corp. has started the processing of clinical samples to evaluate its TeloView platform to identify multiple myeloma (MM) patients at high-risk of developing treatment resistance. The study is the second being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical […] July 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Jul 2022 Radiopharmaceuticals gain traction for cancer theranostics potential After decades of neglect from big pharma, radiopharmaceuticals are generating major oncology deals globally. This could lead to a boom in cancer drugs that can serve as both treatments and diagnostics, or “theranostics.” Over the last few years, there has been big activity from companies developing drugs that use radioactivity to destroy tumors. Just this […] July 14, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2022 Development of cancer therapeutics accelerated by end-to-end single-cell multi-omics services Solid tumor assays have been launched by Mission Bio Inc., through its Pharma Assay Development (PAD) services. The availability of this new service offering from Mission Bio, a high-throughput single-cell DNA and multi-omics analysis company, will help accelerate the development of cancer therapeutics. It will do so by reducing the time and cost associated with […] July 13, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 Legochem Bioscience signs agreement with Glycotope to develop cancer drug A company from South Korea has signed a research collaboration and license agreement with a German business to develop a cancer fighting drug. Seoul-based Legochem Biosciences Inc and Berlin-based Glycotope GmbH will develop an antibody drug conjugate (ADC) by combining LBC’s technology with one of Glycotope’s investigational tumor targeting antibodies. ADCs are a class of […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 First patient receives new immunotherapy drug for HIV in clinical trial A new class of bispecific protein immunotherapy, being developed for patients with human immunodeficiency virus (HIV) infection, has been given to the first patient in a clinical trial. Immunocare Holdings plc, a UK-based, commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad […] July 12, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2022 AI being used to perform molecular analysis of biopsies from bowel disease patients Artificial intelligence will be used to perform molecular analysis of biopsies from unidentified Inflammatory Bowel Disease (IBD) patients in a bid to help those with immune diseases and cancer. Athos Therapeutics, a late-stage preclinical, California-based biotech company uses artificial intelligence to develop small molecule therapeutics for immune-mediated diseases and cancer, announced this week (July 11) […] July 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email